Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$3.7 billion.

  • ImmunityBio's Retained Earnings fell 1157.73% to -$3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 billion, marking a year-over-year decrease of 1157.73%. This contributed to the annual value of -$3.4 billion for FY2024, which is 1396.38% down from last year.
  • Per ImmunityBio's latest filing, its Retained Earnings stood at -$3.7 billion for Q3 2025, which was down 1157.73% from -$3.6 billion recorded in Q2 2025.
  • ImmunityBio's 5-year Retained Earnings high stood at -$1.7 billion for Q1 2021, and its period low was -$3.7 billion during Q3 2025.
  • Its 5-year average for Retained Earnings is -$2.7 billion, with a median of -$2.6 billion in 2023.
  • As far as peak fluctuations go, ImmunityBio's Retained Earnings plummeted by 16299.69% in 2021, and later plummeted by 1144.28% in 2025.
  • Over the past 5 years, ImmunityBio's Retained Earnings (Quarter) stood at -$2.0 billion in 2021, then fell by 21.23% to -$2.4 billion in 2022, then dropped by 24.52% to -$3.0 billion in 2023, then fell by 13.96% to -$3.4 billion in 2024, then decreased by 9.62% to -$3.7 billion in 2025.
  • Its Retained Earnings stands at -$3.7 billion for Q3 2025, versus -$3.6 billion for Q2 2025 and -$3.5 billion for Q1 2025.